Sep 29, 2021 / 03:00PM GMT
Ron Moldaver - Editas Medicine, Inc. - IR
Good morning, everyone. Thank you for joining today's webinar. Today, we plan to review clinical data from Editas Medicine EDIT-101 program, which is currently being used in the Phase 1/2 BRILLIANCE trial for the treatment of CEP290-related retinal degeneration.
As a formality, there may be some forward-looking statements during this webinar. Various remarks that we make about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigations Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factor section of our most recent Annual Report on Form 10-K and our subsequent filings with the SEC. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements even if our views change.
With that, I'd like to hand it over to our Chief Executive
Editas Medicine Inc EDIT-101 Clinical Data Review Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers